Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cann Group Limited (CAN.AX) is an Australian cannabis company focused on the cultivation, production, and distribution of medicinal cannabis products. It operates primarily in Australia, leveraging its licenses for cultivation and manufacturing to position itself in a rapidly growing market, driven by increasing demand for medical cannabis.
Cann Group generates revenue through the sale of medicinal cannabis products, which are distributed to pharmacies and healthcare providers. The company benefits from regulatory licenses that provide a competitive edge in the Australian market, allowing it to capture a growing patient base seeking alternative therapies.
Changes in Australian cannabis regulations that could expand market access
Patient enrollment rates for medicinal cannabis prescriptions
Partnerships with healthcare providers for product distribution
Market sentiment regarding the cannabis sector overall
Regulatory changes that could restrict cannabis use or increase compliance costs
Market saturation as more competitors enter the medicinal cannabis space
Emergence of larger pharmaceutical companies entering the cannabis market
Price competition from other licensed producers
Negative cash flow impacting operational sustainability
Potential liquidity issues given the current current ratio of 0.42
moderate - The demand for medicinal cannabis may be somewhat insulated from economic downturns, but overall consumer spending trends can still impact growth.
Interest rates affect Cann Group's financing costs for expansion and operational activities, potentially impacting its valuation multiples if rates rise significantly.
minimal - The company has a manageable debt-to-equity ratio of 0.44, indicating limited reliance on external credit.
growth - Investors looking for exposure to the expanding medicinal cannabis market may find Cann Group appealing.
high - The stock has demonstrated significant volatility, with a 1-year return of -73.5%.
